Tenaya Therapeutics (TNYA) closed at $0.35 on November 13, 2026, up 0.6% from the previous close, on volume of 1,265,934 shares (30-day average 3,348,893).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Globe Newswire (Mon, 14-Sep 8:30 AM ET)
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
Globe Newswire (Thu, 3-Sep 4:30 PM ET)
Market Chameleon (Thu, 5-Mar 6:06 AM ET)
Tenaya Therapeutics Set to Spotlight Genetic Heart Therapies at H.C. Wainwright Conference
Market Chameleon (Fri, 10-Oct 7:10 AM ET)
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Tenaya Therapeutics trades on the NASDAQ stock market under the symbol TNYA.
As of November 13, 2026, TNYA stock price was flat at $0.35 with 1,265,934 million shares trading.
TNYA has a beta of 3.00, meaning it tends to be more sensitive to market movements. TNYA has a correlation of 0.13 to the broad based SPY ETF.
TNYA has a market cap of $79.59 million. This is considered a Micro Cap stock.
Last quarter Tenaya Therapeutics reported $2 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $847,000 and exceeded earnings estimates by $.02.
In the last 3 years, TNYA traded as high as $7.01 and as low as $.30.
The top ETF exchange traded funds that TNYA belongs to (by Net Assets): VTI, VXF, IBB, PRFZ, QQQS.
TNYA has underperformed the market in the last year with a price return of -74.5% while the SPY ETF gained +13.4%. TNYA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -52.4% and -5.0%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
TNYA support price is $.33 and resistance is $.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNYA shares will trade within this expected range on the day.
